Actinium Pharmaceuticals Statistics
Share Statistics
Actinium Pharmaceuticals has 31.20M shares outstanding. The number of shares has increased by 12.36% in one year.
| Shares Outstanding | 31.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.40M |
| Failed to Deliver (FTD) Shares | 939 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 1.45M, so 4.66% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short % of Shares Out | 4.66% |
| Short % of Float | 4.78% |
| Short Ratio (days to cover) | 5.72 |
Valuation Ratios
The PE ratio is -2.77 and the forward PE ratio is -2.61.
| PE Ratio | -2.77 |
| Forward PE | -2.61 |
| PS Ratio | 1668.5 |
| Forward PS | 6.1 |
| PB Ratio | 3.72 |
| P/FCF Ratio | -2.85 |
| PEG Ratio | n/a |
Enterprise Valuation
Actinium Pharmaceuticals Inc. has an Enterprise Value (EV) of 60.58M.
| EV / Earnings | -1.24 |
| EV / Sales | 747.96 |
| EV / EBITDA | -1.18 |
| EV / EBIT | -1.17 |
| EV / FCF | -1.28 |
Financial Position
The company has a current ratio of 9.21, with a Debt / Equity ratio of 0.
| Current Ratio | 9.21 |
| Quick Ratio | 9.21 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.34% and return on capital (ROIC) is -134.89%.
| Return on Equity (ROE) | -1.34% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -134.89% |
| Revenue Per Employee | 1.65K |
| Profits Per Employee | -996.29K |
| Employee Count | 49 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -74.13% in the last 52 weeks. The beta is 0.15, so Actinium Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -74.13% |
| 50-Day Moving Average | 1.47 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 56.2 |
| Average Volume (20 Days) | 312.58K |
Income Statement
In the last 12 months, Actinium Pharmaceuticals had revenue of 81.00K and earned -48.82M in profits. Earnings per share was -1.83.
| Revenue | 81.00K |
| Gross Profit | 81.00K |
| Operating Income | -51.92M |
| Net Income | -48.82M |
| EBITDA | -51.13M |
| EBIT | -51.92M |
| Earnings Per Share (EPS) | -1.83 |
Balance Sheet
The company has 76.68M in cash and 2.11M in debt, giving a net cash position of 74.56M.
| Cash & Cash Equivalents | 76.68M |
| Total Debt | 2.11M |
| Net Cash | 74.56M |
| Retained Earnings | -337.58M |
| Total Assets | 82.11M |
| Working Capital | 71.77M |
Cash Flow
In the last 12 months, operating cash flow was -47.34M and capital expenditures -153.00K, giving a free cash flow of -47.49M.
| Operating Cash Flow | -47.34M |
| Capital Expenditures | -153.00K |
| Free Cash Flow | -47.49M |
| FCF Per Share | -1.78 |
Margins
Gross margin is 10.00K%, with operating and profit margins of -6.41M% and -6.03M%.
| Gross Margin | 10.00K% |
| Operating Margin | -6.41M% |
| Pretax Margin | -6.03M% |
| Profit Margin | -6.03M% |
| EBITDA Margin | -63.12K% |
| EBIT Margin | -64.10K% |
| FCF Margin | -58.63K% |
Dividends & Yields
ATNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -129.79% |
| FCF Yield | -107.96% |
Analyst Forecast
The average price target for ATNM is $5, which is 254.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 254.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Aug 11, 2020. It was a backward split with a ratio of 1:30.
| Last Split Date | Aug 11, 2020 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -6.53 |
| Piotroski F-Score | 2 |